Literature DB >> 23844574

Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.

Michael D Shultz1, Atwood K Cheung, Christina A Kirby, Brant Firestone, Jianmei Fan, Christine Hiu-Tung Chen, Zhouliang Chen, Donovan N Chin, Lucian Dipietro, Aleem Fazal, Yun Feng, Pascal D Fortin, Ty Gould, Bharat Lagu, Huangshu Lei, Francois Lenoir, Dyuti Majumdar, Etienne Ochala, M G Palermo, Ly Pham, Minying Pu, Troy Smith, Travis Stams, Ronald C Tomlinson, B Barry Touré, Michael Visser, Run Ming Wang, Nigel J Waters, Wenlin Shao.   

Abstract

Tankyrase 1 and 2 have been shown to be redundant, druggable nodes in the Wnt pathway. As such, there has been intense interest in developing agents suitable for modulating the Wnt pathway in vivo by targeting this enzyme pair. By utilizing a combination of structure-based design and LipE-based structure efficiency relationships, the core of XAV939 was optimized into a more stable, more efficient, but less potent dihydropyran motif 7. This core was combined with elements of screening hits 2, 19, and 33 and resulted in highly potent, selective tankyrase inhibitors that are novel three pocket binders. NVP-TNKS656 (43) was identified as an orally active antagonist of Wnt pathway activity in the MMTV-Wnt1 mouse xenograft model. With an enthalpy-driven thermodynamic signature of binding, highly favorable physicochemical properties, and high lipophilic efficiency, NVP-TNKS656 is a novel tankyrase inhibitor that is well suited for further in vivo validation studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23844574     DOI: 10.1021/jm400807n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  33 in total

Review 1.  Small-molecule inhibitors of Wnt signaling pathway: towards novel anticancer therapeutics.

Authors:  Shilong Zheng; Jiawang Liu; Yanyuan Wu; Tien L Huang; Guangdi Wang
Journal:  Future Med Chem       Date:  2015-12-16       Impact factor: 3.808

Review 2.  Chemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative Medicine.

Authors:  L Lum; C Chen
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

3.  Fragment-Based Drug Design of Novel Pyranopyridones as Cell Active and Orally Bioavailable Tankyrase Inhibitors.

Authors:  Javier de Vicente; Parcharee Tivitmahaisoon; Pamela Berry; David R Bolin; Daisy Carvajal; Wei He; Kuo-Sen Huang; Cheryl Janson; Lena Liang; Christine Lukacs; Ann Petersen; Hong Qian; Lin Yi; Yong Zhuang; Johannes C Hermann
Journal:  ACS Med Chem Lett       Date:  2015-08-04       Impact factor: 4.345

4.  Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling.

Authors:  Hui Wang; Bo Lu; Johnny Castillo; Yue Zhang; Zinger Yang; Gregory McAllister; Alicia Lindeman; John Reece-Hoyes; John Tallarico; Carsten Russ; Greg Hoffman; Wenqing Xu; Markus Schirle; Feng Cong
Journal:  J Biol Chem       Date:  2016-05-26       Impact factor: 5.157

5.  A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.

Authors:  Malini Menon; Richard Elliott; Leandra Bowers; Nicolae Balan; Rumana Rafiq; Sara Costa-Cabral; Felix Munkonge; Ines Trinidade; Roderick Porter; Andrew D Campbell; Emma R Johnson; Christina Esdar; Hans-Peter Buchstaller; Birgitta Leuthner; Felix Rohdich; Richard Schneider; Owen Sansom; Dirk Wienke; Alan Ashworth; Christopher J Lord
Journal:  Sci Rep       Date:  2019-01-17       Impact factor: 4.379

6.  From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis.

Authors:  William G Devine; Rosario Diaz-Gonzalez; Gloria Ceballos-Perez; Domingo Rojas; Takashi Satoh; Westley Tear; Ranae M Ranade; Ximena Barros-Álvarez; Wim G J Hol; Frederick S Buckner; Miguel Navarro; Michael P Pollastri
Journal:  ACS Infect Dis       Date:  2017-02-08       Impact factor: 5.084

Review 7.  WNT signalling in prostate cancer.

Authors:  Virginia Murillo-Garzón; Robert Kypta
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

Review 8.  WNT Signaling in Cardiac and Vascular Disease.

Authors:  Sébastien Foulquier; Evangelos P Daskalopoulos; Gentian Lluri; Kevin C M Hermans; Arjun Deb; W Matthijs Blankesteijn
Journal:  Pharmacol Rev       Date:  2018-01       Impact factor: 25.468

9.  LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors.

Authors:  Marc de la Roche; Ashraf E K Ibrahim; Juliusz Mieszczanek; Mariann Bienz
Journal:  Cancer Res       Date:  2014-01-13       Impact factor: 12.701

Review 10.  Tankyrases: structure, function and therapeutic implications in cancer.

Authors:  Teemu Haikarainen; Stefan Krauss; Lari Lehtio
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.